No Data
Hong Kong stocks move | KPC Pharmaceuticals-B (02171) surged nearly 14% in early trading. KJC-2219 has launched clinical trials, and CT041 for treating stomach cancer is expected to submit NDA in the first half of the year.
Kejia Pharmaceutical-B (02171) rose nearly 14% in the early session, and as of the time of writing, it is up 12.94%, priced at 11 Hong Kong dollars, with a turnover of 94.1106 million Hong Kong dollars.
Individual Investors Are CARsgen Therapeutics Holdings Limited's (HKG:2171) Biggest Owners and Were Rewarded After Market Cap Rose by HK$510m Last Week
CARSGEN-B: CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESSIN HONG KONG AND DATE OF BOARD MEETING
Express News | CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic Cd19/Cd20 CAR-T Therapy
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
Kojie Pharmaceutical has announced the initiation of a researcher-initiated clinical trial for the universal CD19/CD20 CAR-T.
Shanghai, December 31, 2024 /PR Newswire/ -- Koji Pharmaceuticals (stock code: 2171.HK), an innovative CAR-T cell therapy company primarily focused on treating hematologic malignancies and solid tumors, announced that its independently developed universal CAR-T cell therapy candidate KJ-C2219, targeting CD19/CD20, has initiated a clinical trial (IIT) in China for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). KJ-C2219 is based on THANK-u.
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% Drop
